comparemela.com

Latest Breaking News On - Pacira biosciences daily - Page 13 : comparemela.com

HC Wainwright Lowers Pacira BioSciences (NASDAQ:PCRX) Price Target to $68 00

Pacira BioSciences (NASDAQ:PCRX – Get Free Report) had its target price dropped by equities researchers at HC Wainwright from $71.00 to $68.00 in a research report issued to clients and investors on Thursday, FlyOnTheWall reports. HC Wainwright’s price target suggests a potential upside of 82.35% from the company’s previous close. HC Wainwright also issued estimates […]

Peregrine Capital Management LLC Buys 5,521 Shares of Pacira BioSciences, Inc (NASDAQ:PCRX)

Peregrine Capital Management LLC increased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 3.1% during the 1st quarter, HoldingsChannel reports. The firm owned 184,695 shares of the company’s stock after purchasing an additional 5,521 shares during the period. Peregrine Capital Management LLC’s holdings in Pacira BioSciences were worth $7,537,000 as […]

Pacira BioSciences (NASDAQ:PCRX) Shares Down 2 4% on Insider Selling

Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report)’s stock price was down 2.4% on Monday after an insider sold shares in the company. The company traded as low as $36.92 and last traded at $36.97. Approximately 253,159 shares traded hands during mid-day trading, a decline of 55% from the average daily volume of 559,643 shares. The […]

Brokerages Set Pacira BioSciences, Inc (NASDAQ:PCRX) Target Price at $62 73

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price […]

Pacira BioSciences, Inc (NASDAQ:PCRX) Given Consensus Recommendation of Moderate Buy by Brokerages

Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) has earned an average rating of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price objective […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.